51 related articles for article (PubMed ID: 27643573)
21. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.
Shamaa S; Laimon N; Aladle DA; Azmy E; Elghannam DM; Salem DA; Taalab MM
Hematology; 2014 Jan; 19(1):22-30. PubMed ID: 23540998
[TBL] [Abstract][Full Text] [Related]
22. [Prognostic significance of early assessment of minimal residual disease in acute myeloid leukemia with mutated NPM1 patients].
Zhao T; Zhu HH; Wang J; Jia JS; Yang SM; Jiang H; Lu J; Chen H; Xu LP; Zhang XH; Jiang B; Ruan GR; Wang DB; Huang XJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2017 Jan; 38(1):10-16. PubMed ID: 28219218
[No Abstract] [Full Text] [Related]
23. Allogeneic hematopoietic stem cell transplantation could improve survival of cytogenetically normal adult acute myeloid leukemia patients with DNMT3A mutations.
Xu Y; Sun Y; Shen H; Ding L; Yang Z; Qiu H; Sun A; Chen S; Wu D
Am J Hematol; 2015 Nov; 90(11):992-7. PubMed ID: 26223865
[TBL] [Abstract][Full Text] [Related]
24. Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant.
Ahn JS; Kim JY; Kim HJ; Kim YK; Lee SS; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Minden MD; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
Ann Hematol; 2016 Jan; 95(2):301-10. PubMed ID: 26537612
[TBL] [Abstract][Full Text] [Related]
25. Pre-transplant Quantitative Determination of NPM1 Mutation Significantly Predicts Outcome of AIlogeneic Hematopoietic Stem Cell Transplantation in Patients with Normal Karyotype AML in Complete Remission.
Karas M; Steinerova K; Lysak D; Hrabetova M; Jungova A; Sramek J; Jindra P; Polivka J; Holubec L
Anticancer Res; 2016 Oct; 36(10):5487-5498. PubMed ID: 27798920
[TBL] [Abstract][Full Text] [Related]
26. Karyotype plus NPM1 mutation status defines a group of elderly patients with AML (≥60 years) who benefit from intensive post-induction consolidation therapy.
Sperr WR; Zach O; Pöll I; Herndlhofer S; Knoebl P; Weltermann A; Streubel B; Jaeger U; Kundi M; Valent P
Am J Hematol; 2016 Dec; 91(12):1239-1245. PubMed ID: 27643573
[TBL] [Abstract][Full Text] [Related]
27. Conventional chemotherapy or hypomethylating agents for older patients with acute myeloid leukaemia?
Ferrara F
Hematol Oncol; 2014 Mar; 32(1):1-9. PubMed ID: 23512815
[TBL] [Abstract][Full Text] [Related]
28. Acute myeloid leukemia: 2013 update on risk-stratification and management.
Estey EH
Am J Hematol; 2013 Apr; 88(4):318-27. PubMed ID: 23526416
[TBL] [Abstract][Full Text] [Related]
29. Is there justification for 4 cycles of consolidation therapy in AML?
Schlenk RF
Best Pract Res Clin Haematol; 2016 Dec; 29(4):341-344. PubMed ID: 27890257
[TBL] [Abstract][Full Text] [Related]
30. Prognostic Significance of Complex Karyotypes in Acute Myeloid Leukemia.
Daneshbod Y; Kohan L; Taghadosi V; Weinberg OK; Arber DA
Curr Treat Options Oncol; 2019 Feb; 20(2):15. PubMed ID: 30741367
[TBL] [Abstract][Full Text] [Related]
31. Clinical studies of acute myeloid leukemia in the Japan Adult Leukemia Study Group.
Miyawaki S
Int J Hematol; 2012 Aug; 96(2):171-7. PubMed ID: 22851055
[TBL] [Abstract][Full Text] [Related]
32. Optimal Post-Remission Consolidation Therapy in Patients with AML.
Jimenez-Chillon C; Dillon R; Russell N
Acta Haematol; 2024; 147(2):147-158. PubMed ID: 38008085
[TBL] [Abstract][Full Text] [Related]
33. Diagnosis and Therapy of Acute Myeloid Leukemia in the Era of Molecular Risk Stratification.
Komanduri KV; Levine RL
Annu Rev Med; 2016; 67():59-72. PubMed ID: 26473413
[TBL] [Abstract][Full Text] [Related]
34. The important role of intensive induction chemotherapy in the treatment of acute myeloid leukemia.
Lin TL; Pagano L
Expert Rev Hematol; 2021 Mar; 14(3):303-314. PubMed ID: 33593202
[No Abstract] [Full Text] [Related]
35. Diagnosis and treatment of therapy-related acute myeloid leukemia.
Strickland SA; Vey N
Crit Rev Oncol Hematol; 2022 Mar; 171():103607. PubMed ID: 35101585
[TBL] [Abstract][Full Text] [Related]
36. Consolidation chemotherapy in AML: Are we playing with a full deck of cards?
Stone RM
Best Pract Res Clin Haematol; 2022 Dec; 35(4):101408. PubMed ID: 36517130
[TBL] [Abstract][Full Text] [Related]
37. What's new in consolidation therapy in AML?
Schlenk RF; Jaramillo S; Müller-Tidow C
Semin Hematol; 2019 Apr; 56(2):96-101. PubMed ID: 30926097
[TBL] [Abstract][Full Text] [Related]
38. Acute myeloblastic leukaemia in the elderly: biology, prognostic factors and treatment.
Manoharan A
Int J Hematol; 1998 Oct; 68(3):235-43. PubMed ID: 9846008
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
